MSD | Jotup

University of Iowa College of Dentistry and Dental Clinics research finds new app supports improved care for persons living with dementia

Retrieved on:

Giovedì, Febbraio 1, 2024

IOWA CITY, Iowa and WASHINGTON, Feb. 1, 2024 /PRNewswire/ -- Caregivers of people living with dementia reported a significant increase in their knowledge, skills, and a more positive attitude in delivering oral hygiene care, leading to higher confidence in providing care, through the use of a mobile application (app), according to new research from the University of Iowa College of Dentistry and Dental Clinics and the University of Iowa College of Public Health. The study, led by Leonardo Marchini, DDS, MSD, PhD, and Sato Ashida, PhD, assessed the use of an app, Dental.Aging.Tips, as a tool to inform and teach caregivers how to help older adults with their oral health.

Key Points:

"It is tremendously encouraging that the newly developed Dental.Aging.Tips app used in this study was widely accepted, and improved caregivers' attitudes, knowledge, and abilities to provide oral hygiene care."
Key takeaways from the study include:
The Dental.Aging.Tips App improved perceptions related to oral hygiene care provision among both family and paid caregivers.
Caregivers found the information extremely useful and helpful in improving the oral hygiene care they provide to persons living with dementia.
The report was sponsored by the Delta Dental Institute , which supports research-based exploration of care delivery models like emerging technology and mobile apps that improve health care outcomes and advance patient-centered care.

Financial update on Harpoon Therapeutics acquisition by Merck (MSD)

Retrieved on:

Martedì, Gennaio 30, 2024

MSD, Patient, Therapy, Biotechnology, Cancer, Sale, Acquisition, MRK, Pharmaceutical industry

LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.

Key Points:

LONDON, 19 January 2024: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, provides a financial update on its expected returns from the Harpoon Therapeutics (NASDAQ: HARP) ("Harpoon") acquisition by Merck (NYSE: MRK) following the announcement that Merck (known as MSD outside the United States and Canada), through a subsidiary, agreed to acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million.
The sale of Harpoon is expected to deliver net proceeds to Arix of approximately $18.9 million (£14.9 million [1]).
This acquisition by Merck provides significant potential for bringing life-saving treatment to cancer patients as they enhance their oncology pipeline.
[1] At prevailing GBP/USD FX rate on 18 January 2024.

Unnatural Products, Inc. Enters Research Collaboration with Merck

Retrieved on:

Martedì, Gennaio 23, 2024

MSD, Entrepreneurship, Chemistry, Head, Macrocycle, Merck & Co., Antibody, Therapy, UNP, Merck, Nature, Pharmaceutical industry

“This collaboration with Merck leverages macrocycles against one of the most challenging oncology targets and is a testament to the progress we have made in intracellular targeting and the importance of finding new ways to tackle the high-hanging fruit in oncology,” said Cameron Pye, CEO and Co-Founder .

Key Points:

“This collaboration with Merck leverages macrocycles against one of the most challenging oncology targets and is a testament to the progress we have made in intracellular targeting and the importance of finding new ways to tackle the high-hanging fruit in oncology,” said Cameron Pye, CEO and Co-Founder .
“Merck continues to leverage our strong medicinal chemistry capabilities to advance our oncology pipeline,” said Rob Garbaccio , vice president and head, discovery chemistry, Merck Research Laboratories.
“We look forward to working with the Unnatural Products team to develop candidates towards this challenging oncology target.”
Nature’s solution to hard targets: Macrocycles
Macrocycles and cyclic peptides offer an opportunity to radically expand the druggable genome.
Naturally derived macrocycles have been used as essential medicines across a variety of indications for decades.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on:

Lunedì, Gennaio 22, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points:

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
“Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business

Retrieved on:

Mercoledì, Gennaio 17, 2024

MSD, BDT, Hand, Centerview Partners, LLP, RCM, Adjustment, Partnership, Kirkland & Ellis, McDermott Will & Emery, Acquisition, J. P. Morgan, Internationalized domain name, Reliability-centered maintenance, Real estate

MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation's largest health systems. In addition, the Company announced that it expects to release financial results for the fourth quarter and full year ended December 31, 2023, and its 2024 outlook and will host a conference call at 8:00 a.m. ET on Tuesday, February 27, 2024, to discuss the results and business outlook.

Key Points:

ET on Tuesday, February 27, 2024, to discuss the results and business outlook.
Upon closing, R1 begins its 10-year partnership with Providence for comprehensive revenue cycle services that leverage the breadth of integrated technology and services capabilities of both R1 and Acclara.
Centerview Partners LLC and J.P. Morgan acted as financial advisors to R1, and Perkins Coie LLP, Kirkland & Ellis LLP, and Baker Donelson acted as legal counsel.
BDT & MSD Partners acted as financial advisor to Providence, and McDermott Will & Emery and ArentFox Schiff LLP acted as legal counsel.

DEPARTMENT OF THE NAVY AWARDS NOBLIS MSD $93 MILLION CONTRACT

Retrieved on:

Mercoledì, Gennaio 17, 2024

MSD, Science, Noblis, Navy, Database, Management

Reston, Va., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today announced that it has been awarded the NAVSEA PMS 339 Fleet Introduction contract valued at more than $93 million.

Key Points:

Reston, Va., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Noblis MSD, a Noblis subsidiary and leading provider of science, technology and engineering services to the Department of Defense, today announced that it has been awarded the NAVSEA PMS 339 Fleet Introduction contract valued at more than $93 million.
Under this contract, the Noblis team will continue providing on-site, waterfront-based administrative, logistics, manning and training, commissioning, network administration and database development services at the Navy's Fleet Concentration areas and shipbuilding yards.
“The Noblis MSD Fleet Introduction team is an accomplished and experienced technical team,” said Glenn Hickok , president of Noblis MSD.
“On day one, they have an acute understanding of the requirements needed to support the customer and its crews.”

Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Carcinoma (RCC) at an Increased Risk of Recurrence Following Nephrectomy

Retrieved on:

Sabato, Gennaio 27, 2024

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.

Key Points:

At 48 months, the estimated OS rate was 91.2% for patients who received KEYTRUDA compared to 86.0% for patients who received placebo.
Treatment-related adverse events (TRAEs) occurred in 79.1% of patients (n=386) in the KEYTRUDA arm and 53.0% of patients (n=263) in the placebo arm.
Grade 3-4 TRAEs occurred in 18.6% of patients in the KEYTRUDA arm and 1.2% of patients in the placebo arm.
Treatment-related adverse events resulting in discontinuation of any treatment occurred in 18.2% of patients in the KEYTRUDA arm and 0.8% of patients in the placebo arm.

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized Muscle-Invasive and Locally Advanced Urothelial Carcinoma After Surgery

Retrieved on:

Venerdì, Gennaio 26, 2024

Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.

Key Points:

Median DFS was 29.0 months (95% CI, 21.8-not evaluable [NE]) for KEYTRUDA and 14.0 months (95% CI, 9.7-20.20) for observation, an improvement of 15 months.
AMBASSADOR (A031501)/KEYNOTE-123 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT03244384 ) evaluating KEYTRUDA versus observation for the adjuvant treatment of patients with localized MIUC and locally advanced resectable urothelial carcinoma.
17.4% of patients receiving KEYTRUDA withdrew from the trial without event versus 27.2% from the observation arm.
Grade ≥3 adverse events occurred in 48.4% of patients receiving KEYTRUDA versus 31.8% of patients under observation.

Merck Announces Second-Quarter 2024 Dividend

Retrieved on:

Martedì, Gennaio 23, 2024

Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, MRK

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024.

Key Points:

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common stock for the second quarter of 2024.
Payment will be made on April 5, 2024, to shareholders of record at the close of business on March 15, 2024.

Merck to Hold Fourth-Quarter and Full-Year 2023 Sales and Earnings Conference Call Feb. 1

Retrieved on:

Venerdì, Gennaio 19, 2024

Oncology, Health, FDA, General Health, Clinical Trials, Pharmaceutical, Biotechnology, MSD, News, MRK, Webcast

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m.

Key Points:

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2023 sales and earnings conference call with institutional investors and analysts at 9:00 a.m.
During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2024.
Investors, journalists and the general public may access a live audio webcast of the call via this weblink .
A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures, and slides highlighting the results, will be available at www.merck.com .